Skip Navigation

European Heart Journal 2002 23(24):1922-1930; doi:10.1053/euhj.2002.3281
Copyright © 2002 by the European Society of Cardiology.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Marang-van de Mheen, P.J.
Right arrow Articles by Klazinga, N.S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marang-van de Mheen, P.J.
Right arrow Articles by Klazinga, N.S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Cost-effectiveness of a family and DNA based screening programme on familial hypercholesterolaemia in The Netherlands

P.J. Marang-van de Mheena,b,f1, A.H.A. ten Asbroeka, L. Bonneuxc, G.J. Bonsela and N.S. Klazingaa

a Department of Social Medicine, Academic Medical Center, Amsterdam, The Netherlands
b Department of Medical Decision Making, Leiden University Medical Centre, The Netherlands
c Department of Public Health, Erasmus University, Rotterdam, The Netherlands

revised April 29, 2002; accepted May 1, 2002

Abstract

Aims To estimate the cost-effectiveness of the current screening programme on Familial Hypercholesterolaemia (FH) in relatives of diagnosed FH-patients in The Netherlands.

Methods and Results Data from 2229 screened FH-relatives, including age, sex, risk factor status and screening outcome, were combined with the Framingham risk function and national disease-specific cost data to arrive at a model-based comparison of survival and costs, with and without the screening programme. Cost-effectiveness ratios were computed for various treatment strategies, with no screening as reference. Costs per life year gained varied between 25·5- and 32-thousand Euros, depending upon the precise treatment strategy after a positive screen. The costs for screening (tracing the FH-positive individuals) were much lower than the follow-up costs (treatment), of which 80% were costs for statins. Consequently, the costs per life year gained of alternative screening programmes are about the same.

Conclusion The cost-effectiveness ratio of FH screening is within the range requiring explicit political consideration in The Netherlands. As the costs of statin treatment are the single most important determinant of costs, policy decisions reduce to decisions on the acceptability of statin treatment for this risk group. Pending major changes in statin price, clear guidelines should be developed on how screen positive individuals should be treated, since not all of them have an elevated cholesterol level. Copyright 2002 The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved.

Key Words: Familial hypercholesterolaemia, screening, The Netherlands, cholesterol, statin treatment.

f1 Correspondence: Dr P. J. Marang-van de Mheen, Department of Medical Decision Making, K6-R, Leiden University Medical Centre, PO Box 9600, 2300 RC Leiden, The Netherlands.

References

  1. Eur Heart J. 2001;22:554–572[Abstract/Free Full Text]
  2. Jönsson B, Johannesson M, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost effectiveness of cholesterol lowering. Eur Heart J. 1996;17:1001–1007[Abstract/Free Full Text]
  3. Johannesson M, Jönsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med. 1997;336:332–336[Abstract/Free Full Text]
  4. Pharoah PDP, Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ. 1996;312:1443–1448[Abstract/Free Full Text]
  5. Pickin DM, McCabe CJ, Ramsay LE. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart diseae and cost of drug treatment. Heart. 1999;82:325–332[Abstract/Free Full Text]
  6. Goldman L, Goldman PA, Williams LW, Weinstein MC. Cost effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications. Am J Cardiol. 1993;72:75D–79D[CrossRef][Medline]
  7. Motulsky GA. Genetic aspects of familial hypercholesterolemia and its diagnosis. Arteriosclerosis. 1989;9:I3–I7[Medline]
  8. Goldstein JL, Schrott HG, Hazzard WR. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973;52:1544–1568[ISI][Medline]
  9. Slack J. Inheritance of familial hypercholesterolemia. Atherosclerosis Rev. 1979;5:35–66
  10. Goldstein JL, Hobbs H, Brown M. Familial hypercholesterolemia. Scriver CT, Beaudet AL, Sly WS, Valle D. The metabolic basis of inherited disease. New York: McGraw-Hill; 1989. p. 1981–2030
  11. Atherosclerosis. 1999;142:105–112[CrossRef][ISI][Medline]
  12. Umans-Eckenhausen MAW, Defesche JC, Scheerder RLJM, Cliné F, Kastelein JJP. Tracing of patients with Familial Hypercholesterolemia in the Netherlands (in Dutch). Ned Tijdschr Geneeskd. 1999;143:1157–1161[Medline]
  13. Ten Asbroek AHA, Marang-van de Mheen PJ, Defesche JC, Kastelein JJP, Gunning-Schepers LJ. Results from a family and DNA based active identification programme for Familial Hypercholesterolemia. J Epidemiol Commun Health. 2001;55:500–502[Free Full Text]
  14. Polder, JJ, Meerding, WJ, Koopmanschap, MA, Bonneux, L, van der Maas, PJ, Costs of diseases in the Netherlands 1994 (in Dutch), Rotterdam, Erasmus Universiteit, 1997
  15. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256:2823–2828[Abstract]
  16. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA. 1987;257:2176–2180[Abstract]
  17. Neaton JD, Blackburn H, Jacobs D. Serum cholesterol and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med. 1992;152:1490–1500[Abstract]
  18. Bonneux L. Cholesterol-lowering therapy for smokers and non-smokers: a life-table analysis. Lancet. 2000;356:2004–2006[CrossRef][ISI][Medline]
  19. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular risk profiles. Am Heart J. 1991;121:293–298[CrossRef][ISI][Medline]
  20. Public Health Forecast 1997. I The health status (in Dutch). Bilthoven: RIVM; 1997.
  21. Baan, C, Cardiovascular consequences of diabetes mellitus (thesis), Rotterdam, Erasmus University, 1999
  22. Smit, HA, Verschuren, WMM, Bueno de Musquita, Seidell, JC, The Monitoring Project on Risk Factors for Chronic Diseases (MORGEN-project), Bilthoven, The Netherlands, RIVM
  23. Foundation Public Health and Smoking, Annual report 1998, The Hague, 1999
  24. Central Bureau of Statistics, Deaths by primary cause, age and sex, 1995, Voorburg, The Netherlands, CBS, 2000
  25. Mndstat bevolking. 1999;3:32–33
  26. Dutch Institute on Health Care Improvement (CBO), Treatment and prevention of Coronary Heart Disease by lower plasma cholesterol concentration. Consensus cholesterol second revision (in Dutch), Utrecht, The Netherlands, CBO, April 1998
  27. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of Coronary Disease. A meta-analysis of randomised controlled trials. JAMA. 1999;282:2340–2346[Abstract/Free Full Text]
  28. Ramachandran S, French JM, Vanderpump MPJ, Croft P, Neary RH. Using the Framingham model to predict heart disease in the United Kingdom: retrospective study. BMJ. 2000;320:676–677[Free Full Text]
  29. Jensen JM, Gerdes LU, Jensen HK, Christiansen TM, Brorholt-Petersen JU, Faergeman O. Association of coronary heart disease with age-adjusted aortocoronary calcification in patients with familial hypercholesterolemia. J Intern Med. 2000;247:479–484[CrossRef][ISI][Medline]
  30. Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA. 2000;284:311–318[Abstract/Free Full Text]
  31. Krumholz HM, Seeman TE, Merrill SS. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA. 1994;272:1335–1340[Abstract]
  32. Psaty BM, Koepsell TD, Manolio TA. Risk ratios and risk differences in estimating the effect of risk factors for cardiovascular disease in the elderly. J Clin Epidemiol. 1990;43:961–970[CrossRef][ISI][Medline]
  33. Jackson R. Guidelines on preventing cardiovascular disease in clinical practice. BMJ. 2000;320:659–661[Free Full Text]
  34. Marang-van de Mheen, PJ, ten Asbroek, AHA, van Maarle, MC, Stouthard, MEA, Bonsel, GJ, Klazinga, NS, Screening on Familial Hypercholesterolemia in the Netherlands. An evaluation of costs, effects and psychosocial consequences (in Dutch), Amsterdam, 2000
  35. Van Maarle MC, Stouthard MEA, Marang-van de Mheen PJ, Klazinga NS, Bonsel GJ. Follow-up after a familybased genetic screening programme on Familial Hypercholesterolemia: is screening alone enough. BMJ. 2002;324:1367–1368[Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 HeartHome page
H A W Neil, V Seagroatt, D J Betteridge, M P Cooper, P N Durrington, J P Miller, M Seed, R P Naoumova, G R Thompson, R Huxley, et al.
Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
Heart, December 1, 2004; 90(12): 1431 - 1437.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
M. A. Austin, C. M. Hutter, R. L. Zimmern, and S. E. Humphries
Genetic Causes of Monogenic Heterozygous Familial Hypercholesterolemia: A HuGE Prevalence Review
Am. J. Epidemiol., September 1, 2004; 160(5): 407 - 420.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
K. F. Fox
Familial hypercholesterolaemia--screening is effective, but is it cost effective?
Eur. Heart J., December 2, 2002; 23(24): 1892 - 1893.
[PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Marang-van de Mheen, P.J.
Right arrow Articles by Klazinga, N.S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marang-van de Mheen, P.J.
Right arrow Articles by Klazinga, N.S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?